A Pan-European, open label, randomised study comparing the efficacy and cost-effectiveness of Symbicort Maintenance and Reliever Therapy (Symbicort SMART) using a maintenance dose of Symbicort 160/4.5 micrograms of 1 or 2 inhalations twice daily in the treatment of persistent asthma.

Trial Profile

A Pan-European, open label, randomised study comparing the efficacy and cost-effectiveness of Symbicort Maintenance and Reliever Therapy (Symbicort SMART) using a maintenance dose of Symbicort 160/4.5 micrograms of 1 or 2 inhalations twice daily in the treatment of persistent asthma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Sep 2014

At a glance

  • Drugs Budesonide/formoterol (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms EUROSMART; SMART
  • Sponsors AstraZeneca
  • Most Recent Events

    • 06 Nov 2012 Planned number of patients changed from 8000 to 11500.
    • 22 Sep 2010 Results of a subgroup analysis comparing outcomes in smokers versus nonsmokers presented at the 20th Annual Congress of the European Respiratory Society.
    • 19 May 2010 Prospectively planned subgroup analysis assessing the effect of treatment on the fractional excretion of nitric oxide presented at the 106th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top